Insider trade

Brian M Culley, CEO at Lineage Cell Therapeutics, bought ~$37K of Lineage Cell Therapeutics shares.

~$37K
Approx. value · 41K sh @ $0.916
296K
Holds after · shares reported
Traded
Nov 16, 2026
Filed
Nov 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 12, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement (and 3 more items)“On November 12, 2026, Lineage issued a press release announcing financial results for the quarter ended September 30, 2026, a copy of which is furnished as Exhibit 99.1.”
  2. Nov 16, 2026 · this disclosureInsider · 3 insiders in a week, 6th time since 2006CEO purchased ~$37K of LCTX shares in the open market

What came next

  1. Nov 16, 2026Insider · 2 peopleInsiders: 2 purchases (~$37K)
  2. Nov 17, 2026Insider · 2 peopleInsiders: 2 purchases (~$797K)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Lineage Cell Therapeutics

For Lineage Cell Therapeutics, OQRO holds 5 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LCTX page.

Other recent filings by Brian M Culley, President and CEO

The full history of Brian M Culley, President and CEO is on the profile page.

How this filing works

Explore the data

Common questions

Which Lineage Cell Therapeutics (LCTX) insider traded, and how much?

Brian M Culley, CEO at Lineage Cell Therapeutics, bought ~$37K of Lineage Cell Therapeutics shares. 41K shares at $0.92, open market.

When did it happen, and when was it made public?

Traded: Nov 16, 2026. Filed: Nov 17, 2026. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Lineage Cell Therapeutics recently?

For Lineage Cell Therapeutics, OQRO holds 5 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the LCTX page.

Does this mean LCTX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Lineage Cell Therapeutics

Everything OQRO holds on this company is on its LCTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data